Exagen IncNASDAQ:XGN
- LAST PRICE1.4121
- TODAY'S CHANGE (%)0.0021 (0.1489%)
- Bid / Lots1.4000/ 4
- Ask / Lots1.4900/ 5
- Open / Previous Close1.4100 / 1.4100
- Day Range
- 52 Week Range
- Volume3,511
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XGN |
|---|---|---|
| 09:32 ET | 273 | 1.41 |
| 11:44 ET | 150 | 1.4 |
| 12:48 ET | 281 | 1.4075 |
| 01:35 ET | 116 | 1.406 |
| 01:42 ET | 100 | 1.39 |
| 01:46 ET | 722 | 1.385 |
| 02:02 ET | 200 | 1.4 |
| 03:30 ET | 100 | 1.39 |
| 03:52 ET | 100 | 1.4121 |
Today
Exagen Inc. Announces Changes to the Board of Directors, from 8 hours ago by Dow Jones
8 hours ago by Dow JonesPress Release: Exagen Inc. Announces Changes to the Board of Directors, from 8 hours ago by Dow Jones
8 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Exagen Inc | 24.3M | -1.1x | --- |
Global Cord Blood Corp | 167.4M | 2.2x | +20.97% |
Star Equity Holdings Inc | 13.9M | -3.7x | --- |
Streamline Health Solutions Inc | 20.0M | -0.9x | --- |
New York Health Care Inc | 38.9M | 0.0x | --- |
Psychemedics Corp | 14.7M | -3.5x | --- |
Company Information
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Contact Information
- Headquarters
- 1261 Liberty Way Ste CVISTA, CA, United States 92081-8356
- Phone
- 760-560-1501
- Fax
- 302-655-5049
Executives
- Executive Chairperson of the Board
- Tina Nova
- President, Chief Executive Officer, Director
- John Aballi
- Chief Financial Officer, Corporate Secretary
- Kamal Adawi
- Independent Director
- Brian Birk
- Independent Director
- Ana Hooker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.3M |
|---|---|
Revenue (TTM) | $52.5M |
Shares Outstanding | 17.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-1.34 |
Book Value | $1.33 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 0.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -43.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
